Aeroallergen

Phase 1Small molecule

HHamilton Health Sciences Corporation

Aeroallergen is one of 18 small molecule programs targeting Atopic Asthma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Atopic AsthmaActive, not recruiting

Atopic AsthmaPhase 1

Active, not recruiting

Competition

Competitive Landscape

20 competitors in Atopic Asthma

#DrugCompanyPhaseTrials

Xolair

Roche

Phase 3

2 2

Fasenra

AstraZeneca

Phase 3

1 3

Orencia

Bristol-Myers Squibb

Phase 2

1 4

Flovent

PParatek Pharmaceuticals Inc

Phase 2

1 5

Spiriva

Boehringer Ingelheim

Phase 2

1 6

Tezspire

AstraZeneca

Phase 1

1 7

QAW039

Novartis

Phase 2

1 8

Senicapoc

IIcagen

Phase 2

1 9

AMG 333

Amgen

Phase 1

1 10

IMA-638

Pfizer

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Atopic Asthma1 trial

The Effect of Allergen Inhalation on Sputum Myeloid and Plasmacytoid Dendritic Cells in Mild Atopic Asthmatics

Completed·HHamilton Health Sciences Corporation·Phase 1·NCT00625989·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Aeroallergen. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Aeroallergen compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Aeroallergen. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hamilton Health Sciences Corporation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: HHamilton Health Sciences Corporation

Aeroallergen

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Atopic Asthma1 trial

References

Drug Info

Quick Facts

Related News